Av-VITE FB Forte
- Manufacturer
- AvKARE, Inc.
- Effective date
- 2016-04-11
- Label type
- DIETARY SUPPLEMENT
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:27:37
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
STATEMENT OF IDENTITY SECTION
DESCRIPTION: Av-VITE FB Forte Tablets are an orally administered prescription dietary supplement for the management of patients requiring increased folate levels.
Av-VITE FB Forte Tablets should be administered under the supervision of a licensed medical practitioner.
| Supplement Facts | ||
|---|---|---|
| Serving Size: 1 Tablet | ||
| Amount Per Serving | % Daily Value | |
| Vitamin B6 (as Pyridoxine HCl) | 25 mg | 1250% |
| Folic Acid | 2.5 mg | 625% |
| Vitamin B12 (as Cyanocobalamin) | 2 mg | 33333% |
Other Ingredients: Dibasic Calcium Phosphate Dihydrate, Microcrystalline Cellulose, Opadry II Beige 40L17427 (Titanium Dioxide, Polydextrose, Hypromellose 3cP, Hypromellose 6cP, Triacetin, Hypromellose 50cP, Polyethylene Glycol 8000, FD&C Yellow # 6 Aluminum Lake, FD&C Blue # 2 Aluminum Lake, FD&C Red #40 Aluminum Lake), Croscarmellose Sodium, Opadry II Clear #Y-19-7483 (Hypromellose 6cP, Maltodextrin, Hypromellose 3cP, Polyethylene Glycol 400, Hypromellose 50cP) Magnesium Stearate.
Contains: FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake
WARNINGS SECTION
ALLERGY STATEMENT: This product has been manufactured in a facility that also manufactures products containing milk and soy. Individuals with allergic tendencies to these substances should use discretion.
Allergic reactions have been reported following the use of oral folate.
Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body have been associated with cobalamin.
Paresthesia, somnolence, nausea, and headaches have been reported with pyridoxine.
HEALTH CLAIM SECTION
CONTRAINDICATIONS: This product is contraindicated in patients with a known hypersensitivity to any of the components contained in this product.
WARNINGS SECTION
CAUTION: High levels of folic acid may, especially in older adults, hide signs of vitamin B-12 deficiency (such as pernicious anemia), a condition that can cause nerve damage.
WARNINGS SECTION
INTERACTIONS: Drugs which may interact with folate include but are not limited to:
- First generation anticonvulsants (folate may reduce their effectiveness)
- Capecitabine (folate may enhance its toxicity)
- Fluorouracil (folate may enhance its toxicity)
Drugs which may interact with folate metabolism include, but are not limited to:
•Dihydrofolate Reductase Inhibitors
•Fluoxetine
•Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
•Sulfasalazine
•Warfarin
Drugs which may interfere with the absorption of folate from the gastrointestinal tract or decrease plasma levels include, but are not limited to:
•Cholestyramine
•Colestipol
•Oral Contraceptives
•Methylprednisolone
•Pancreatic Enzymes
•Pentamidine
•Smoking and Alcohol
•Sulfasalazine
•Metformin
Drugs which may interact with vitamin B6 include, but are not limited to:
•Levodopa (the action of levodopa may be antagonized by vitamin B6)
Drugs which may interact with vitamin B12 include but are not limited to:
•Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride (may decrease the absorption of vitamin B12).
•Nitrous oxide (can produce a functional vitamin B12 deficiency).
HEALTH CLAIM SECTION
PREGNANCY and NURSING MOTHERS: Av-VITE FB Forte Tablets are not intended for use as a prenatal/postnatal multivitamin for lactating or nonlactating mothers. This product contains only B vitamins. Talk with your medical practitioner before using if pregnant or lactating.
DOSAGE & ADMINISTRATION SECTION
DOSAGE AND ADMINISTRATION: One to two tablets daily or as directed by a licensed medical practitioner.
STORAGE: Store at room temperature 15° to 30°C (59° to 86°F).
HEALTH CLAIM SECTION
HOW SUPPLIED: Av-VITE FB Forte Tablets are round, coated, beige colored tablets imprinted on one side with "V201", and are supplied in bottles of 90 tablets NDC 42291-151-90.
SAFE HANDLING WARNING SECTION
KEEP THIS OUT OF REACH OF CHILDREN.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.
Call your medical practitioner about side effects.
You may report side effects by calling AvKARE, Inc. at 1-855-361-3993 or FDA at 1-800-FDA-1088.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
Mfg. Rev. 06/15
AV 04/16 (P)
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
AvKARE
NDC 42291-151-90
Av-VITE FB Forte
Prescription Folic Acid-Containing Dietary Supplement
90 Tablets
Must be used under the supervision of a physician.
| Supplement Facts | ||
|---|---|---|
| Serving Size: 1 Tablet | ||
| Amount Per Serving | % Daily Value | |
| Vitamin B6
(as Pyridoxine HCl) | 25 mg | 1250% |
| Folic Acid | 2.5 mg | 625% |
| Vitamin B12
(as Cyanocobalamin) | 2 mg | 33333% |
Other Ingredients: Dibasic Calcium Phosphate Dihydrate, Microcrystalline Cellulose, Opadry II Beige 40L17427 (Titanium Dioxide, Polydextrose, Hypromellose 3cP, Hypromellose 6cP, Triacetin, Hypromellose 50cP, Polyethylene Glycol 8000, FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C RED #40 Aluminum Lake), Croscarmellose Sodium, Opadry ll Clear #Y-19-7483 (Hypromellose 6cP, Maltodextrin, Hypromellose 3cP, Polyethylene Glycol 400, Hypromellose 50cP) Magnesium Stearate
Contains: FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake.
DESCRIPTION: Av-VITE FB Forte is an orally administered prescription dietary supplement and should be administered under the supervision of a licensed medical practitioner. See package insert for complete product information.
DIRECTION FOR USE: 1 or 2 tablet(s) daily or as directed by a physician.
WARNING: Keep this and all medications out of the reach of children.
CAUTION: High levels of folic acid may, especially in older adults, hide signs of Vitamin B-12 deficiency (such as
pernicious anemia), a condition that can cause nerve damage.
STORAGE: Store at room temperature, 15ºC to 30ºC (59ºF to 86ºF)
Call your licensed medical practitioner about side effects. You may report side effects by calling AvKARE at
855-361-3993 or FDA at 1-800-FDA-1088.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
Mfg. Rev. 06/15 AV 04/16 (P)


DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 42291-151-90 | EA - Each | 42291-151 | 0ea528c9-8a65-4f89-a451-c9a3468f39d3 | 1 | 2015-12-02 |
| 76439-365-90 | EA - Each | 76439-365 | a5ac6c71-ee4a-4359-8b2f-39ccc69a611c | 1 | 2015-08-04 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CYANOCOBALAMIN | ACTIVE INGREDIENT | P6YC3EG204 | 2 | |
| FOLIC ACID | ACTIVE INGREDIENT | 935E97BOY8 | 2 | |
| PYRIDOXINE HYDROCHLORIDE | ACTIVE INGREDIENT | 68Y4CF58BV | 2 | |
| CYANOCOBALAMIN | ACTIVE MOIETY | P6YC3EG204 | 2 | |
| FOLIC ACID | ACTIVE MOIETY | 935E97BOY8 | 2 | |
| PYRIDOXINE | ACTIVE MOIETY | KV2JZ1BI6Z | 2 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 2 | |
| CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE | INACTIVE INGREDIENT | O7TSZ97GEP | 2 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| Croscarmellose Sodium | INACTIVE INGREDIENT | M28OL1HH48 | 2 | |
| FD&C BLUE NO. 2 | INACTIVE INGREDIENT | L06K8R7DQK | 2 | |
| FD&C RED NO. 40 | INACTIVE INGREDIENT | WZB9127XOA | 2 | |
| FD&C YELLOW NO. 6 | INACTIVE INGREDIENT | H77VEI93A8 | 2 | |
| Magnesium Stearate | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| Maltodextrin | INACTIVE INGREDIENT | 7CVR7L4A2D | 2 | |
| Polydextrose | INACTIVE INGREDIENT | VH2XOU12IE | 2 | |
| Titanium Dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| TRIACETIN | INACTIVE INGREDIENT | XHX3C3X673 | 2 |
Products#
Every source-derived product name is available through these pages.
- Av-VITE FB Forte
- PYRIDOXINE HYDROCHLORIDE, FOLIC ACID, and CYANOCOBALAMIN
- PYRIDOXINE HYDROCHLORIDE
- PYRIDOXINE
- FOLIC ACID
- CYANOCOBALAMIN
- CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
- CELLULOSE, MICROCRYSTALLINE
- Titanium Dioxide
- Polydextrose
- TRIACETIN
- FD&C YELLOW NO. 6
- ALUMINUM OXIDE
- FD&C BLUE NO. 2
- FD&C RED NO. 40
- Croscarmellose Sodium
- Maltodextrin
- Magnesium Stearate
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 42291-151 | 42291-151-90 |
| 76439-365 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SOLUTION / ORAL | 690 mg | ||
| CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE | DIBASIC CALCIUM PHOSPHATE DIHYDRATE | O7TSZ97GEP | TABLET / ORAL | 2442 mg | ||
| Polydextrose | POLYDEXTROSE | VH2XOU12IE | TABLET, EXTENDED RELEASE / ORAL | 22 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | SOLUTION / ORAL | 38 mg | ||
| CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE | DIBASIC CALCIUM PHOSPHATE DIHYDRATE | O7TSZ97GEP | TABLET, EXTENDED RELEASE / ORAL | 1036 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / SUBLINGUAL | 43.2 mg | ||
| Croscarmellose Sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 64 mg | ||
| Croscarmellose Sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | SUSPENSION / ORAL | 150 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / TRANSMUCOSAL | 100 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 11 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | SUSPENSION / ORAL | 100 mg/5ml | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, DELAYED RELEASE / ORAL | 66 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | ELIXIR / ORAL | 12.5 mg/5ml | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | SOAP / TOPICAL | NA | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | TABLET, FILM COATED / ORAL | 1 mg | ||
| Croscarmellose Sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, FOR SUSPENSION / ORAL | 1875 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Maltodextrin | MALTODEXTRIN | 7CVR7L4A2D | TABLET, EFFERVESCENT / ORAL | 14404 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | TABLET / ORAL | 60.02 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Croscarmellose Sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, CHEWABLE / ORAL | 216 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / BUCCAL | 0.01 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET, EXTENDED RELEASE / ORAL | 2.22 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET, FILM COATED / ORAL | 2.5 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, DELAYED RELEASE / ORAL | 0.2 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION, EXTENDED RELEASE / ORAL | 1120 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED PELLETS / ORAL | 4.4 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | SYSTEM / TRANSDERMAL | 22.1 mg | ||
| Maltodextrin | MALTODEXTRIN | 7CVR7L4A2D | TABLET, CHEWABLE / ORAL | 292 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | MOUTHWASH / BUCCAL | 0.01 mg/1ml | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| Maltodextrin | MALTODEXTRIN | 7CVR7L4A2D | PASTE / ORAL | 1050 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, EXTENDED RELEASE / ORAL | 1 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, FOR SUSPENSION / ORAL | 278 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE / ORAL | 16 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GUM, CHEWING / BUCCAL | 182 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING / ORAL | 6 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, DELAYED RELEASE / ORAL | 0.02 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / ORAL | 2 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE | DIBASIC CALCIUM PHOSPHATE DIHYDRATE | O7TSZ97GEP | CAPSULE / ORAL | 400 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| ALUMINUM OXIDE | ALUMINUM OXIDE | LMI26O6933 | SPONGE / TOPICAL | NA | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, LIQUID FILLED / ORAL | 12 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| FD&C RED NO. 40 | FD&C RED NO. 40 | WZB9127XOA | CONCENTRATE / ORAL | 0.04 mg/1ml | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | CAPSULE / ORAL | 4 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, DELAYED RELEASE / ORAL | 789.6 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pyridoxine Hydrochloride | PYRIDOXINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | a56d11c0-b033-4201-85ff-fc710506481a | 2024-10-15 | Warnings, Adverse reactions | PYRIDOXINE HYDROCHLORIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.